Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
BLA
Sort By
Newest First
Sign in
1 / 1
1 / 1
IND, NDA, and BLA
Building a Regulatory Roadmap for IND, NDA, and BLA
Rebecca Lamb-Wharton, Ph.D.; Brenda Schlenk, RPh; Mamadou Diallo, PharmD
PAO-03-24-CL-10
Mar 26, 2024
Priority Review
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
Regeneron
PR-M04-20-NI-025
Apr 17, 2020
BLA
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin
Astellas
PR-M07-19-NI-050
Jul 19, 2019
Biologics License Application
FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) in Adult Patients with Sialorrhea
Merz Worldwide
PR-M03-18-NI-062
Mar 16, 2018
FDA
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
Merck & Co.
PR-M03-18-NI-055
Mar 15, 2018
ADC
Pfizer’s MYLOTARG Demonstrates Favorable Profile
Emilie Branch
Pharma's Almanac
PAO-M07-17-NI-022
Jul 18, 2017
FDA Approval
Amgen’s Vectibix Approved for RAS Metastatic Colorectal Cancer
Guy Tiene
Nice Insight
PAO-M07-17-NI-010
Jul 11, 2017
Biosimilars
FDA Approves Celltrion/Teva BLA for Rituximab Biosimilar
Guy Tiene
Nice Insight
PAO-M07-17-NI-006
Jul 07, 2017
Clinical Trials
Priority Review Given to Kite’s Axicabtagene Ciloleucel
Nice Insight
PAO-M05-17-NI-034
May 31, 2017
